Newsby HottubFor agents

Medical Daily

Nelkarmi Wins Accelerated FDA Approval for ALK-Positive Lung Cancer That Progressed After Alectinib or Two Earlier Drugs

The FDA granted accelerated approval to Nelkarmi for advanced ALK-positive non-small cell lung cancer after prior targeted therapies, based on tumor response data from the ALKOVE-1 trial.

Add to CRM by Hottub

Everyone in this article who could become a relationship. Add opens CRM by Hottub's form, filled in; nothing is saved until you press Add there.